Cargando…

Selective Somatostatin 5 (SST5) and Somatostatin 2 (SST2) Nonpeptide Agonists Potently Suppress Glucose- and Tolbutamide-Stimulated Dynamic Insulin Secretion From Isolated Human Islets

Congenital hyperinsulinism (HI) is the most common cause of persistent hypoglycemia in newborns and infants and arises from dysregulated insulin secretion. Rapid recognition and treatment are vital to prevent seizures, permanent developmental delays, coma, or even death. Very few medical options exi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rico, Elizabeth, Zhao, Jian, Chen, Mi, Kusnetzow, Ana Karin, Zhu, Yun Fei, Betz, Stephen F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Diabetes Mellitus and Glucose Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089509/ http://dx.doi.org/10.1210/jendso/bvab048.663

Ejemplares similares

SAT-169 Selective Nonpeptide Somatostatin Subtype 5 (sst5) Agonists Suppress Glucose- and Sulfonylurea-Induced Insulin Secretion in Rats
por: Sturchler, Emmanuel, et al.
Publicado: (2019)

PSUN304 CRN04777 an Oral, Nonpeptide SST5-selective Somatostatin Agonist Dose Dependently Suppresses Basal and Stimulated Insulin Secretion
por: Ferrara-Cook, Christine, et al.
Publicado: (2022)

SAT-260 Selective Nonpeptide Somatostatin Subtype 5 (sst5) Agonists Suppress Induced Insulin Secretion in Pancreatic Islets from both Rats and Healthy Human Donors
por: Rico-Bautista, Elizabeth, et al.
Publicado: (2019)

MON-089 Discovery and Identification of Late Stage Selective Nonpeptide Somatostatin Subtype 5 (sst5) Agonists for the Treatment of Hyperinsulinemic Hypoglycemia
por: Fowler, Melissa A, et al.
Publicado: (2020)

A selective nonpeptide somatostatin receptor 5 agonist effectively decreases insulin secretion in hyperinsulinism
por: Juliana, Christine A., et al.
Publicado: (2023)

Structural insights into the activation of somatostatin receptor 2 by cyclic SST analogues
por: Bo, Qing, et al.
Publicado: (2022)

DOTA-Derivatives of Octreotide Dicarba-Analogs with High Affinity for Somatostatin sst(2,5) Receptors
por: Pratesi, Alessandro, et al.
Publicado: (2017)

Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 Agonist
por: Zhao, Jian, et al.
Publicado: (2022)

The Truncated Isoform of Somatostatin Receptor5 (sst5TMD4) Is Associated with Poorly Differentiated Thyroid Cancer
por: Puig-Domingo, Manel, et al.
Publicado: (2014)

Epigenetic and post‐transcriptional regulation of somatostatin receptor subtype 5 (SST(5)) in pituitary and pancreatic neuroendocrine tumors
por: Pedraza‐Arevalo, Sergio, et al.
Publicado: (2021)

FRI623 Beta Cell Primary Cilia Mediate Somatostatin Responsiveness Via SSTR3
por: Elizabeth Adamson, Samantha, et al.
Publicado: (2023)

Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers
por: Madan, Ajay, et al.
Publicado: (2022)

In Silico, In Vitro and In Vivo Pharmacodynamic Characterization of Novel Analgesic Drug Candidate Somatostatin SST(4) Receptor Agonists
por: Kántás, Boglárka, et al.
Publicado: (2021)

Somatostatin Receptor Splicing Variant sst5TMD4 Overexpression in Glioblastoma Is Associated with Poor Survival, Increased Aggressiveness Features, and Somatostatin Analogs Resistance
por: Fuentes-Fayos, Antonio C., et al.
Publicado: (2022)

MON-477 Octreotide and ONO-ST-468, a Novel and Potent Somatostatin Receptor Type-2 (SST2) Agonist, Suppress GH Hypersecretion in the Monkey
por: Tanaka, Hirotaka, et al.
Publicado: (2019)

OR23-05 Human Absorption, Metabolism, Excretion, and Absolute Oral Bioavailability of (14)C-CRN00808, an Orally Bioavailable, Nonpeptide, Selective, Somatostatin Receptor 2 (sST2) Biased Agonist for the Treatment of Acromegaly
por: Madan, Ajay, et al.
Publicado: (2020)

The human brain somatostatin interactome: SST binds selectively to P-type family ATPases
por: Solarski, Michael, et al.
Publicado: (2019)

Sodium Glucose Co-Transporter2 (SGLT2) Inhibition for Refractory Hypomagnesemia in Monogenic Diabetes Type 5 (MODY 5)
por: Paul, Anju A, et al.
Publicado: (2021)

SUN-621 Body Weight and Body Composition in Patients with Chronic Pancreatitis Are Associated with Islet Function After Total Pancreatectomy and Islet Cell Transplantation
por: Harindhanavudhi, Tasma, et al.
Publicado: (2020)

Reassessment of SST4 Somatostatin Receptor Expression Using SST4-eGFP Knockin Mice and the Novel Rabbit Monoclonal Anti-Human SST4 Antibody 7H49L61
por: Lupp, Amelie, et al.
Publicado: (2021)

Irisin Precursor FNDC5 and Glycemic Control in Patients With Type 2 Diabetes
por: Lima Mágero, Felipe Rodrigues, et al.
Publicado: (2021)

SAT-429 Final Results from the First in Man Phase 1 Clinical Trial of CRN00808, an Orally Bioavailable sst2-Selective, Nonpeptide Somatostatin Biased Agonist, for the Treatment of Acromegaly: Safety, Pharmacokinetics, Pharmacodynamics, and Midazolam Drug Interaction in Healthy Volunteers
por: Madan, Ajay, et al.
Publicado: (2019)

Comparable Long-Term Glycemic Control and Insulin-Independent Rate at Less Cost By Using Intra-Operative vs. Islet Cell Laboratory Isolation for Total Pancreatectomy With Islet Auto-Transplantation
por: Chaidarun, Sushela S, et al.
Publicado: (2021)

Human Somatostatin SST(4) Receptor Transgenic Mice: Construction and Brain Expression Pattern Characterization
por: Nemes, Balázs, et al.
Publicado: (2021)

MON-141 Non-Islet Cell Tumor Hypoglycemia Due to Relapsed Uterine Carcinosarcoma
por: Caraccio, Donald
Publicado: (2019)

OR14-02 Circadian Regulation of Chromatin State Mediates Pancreatic Islet Incretin Response
por: Weidemann, Benjamin John, et al.
Publicado: (2020)

The SSBP3 Co-Regulator Is a Novel Driver of Islet Cell Structure and Function
por: Toren, Eliana, et al.
Publicado: (2021)

SUN-618 Decision Analysis for Glucagon-Like Peptide Receptor Agonists vs. Sodium-Glucose cotransporter2 Inhibitors in Type 2 Diabetes Mellitus
por: khazaali, Ali Al, et al.
Publicado: (2020)

A Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonist in Kidney Transplant Recipients With Type 2 Diabetes
por: Sato, Tetsuhiko, et al.
Publicado: (2021)

SUN-LB124 Novel Elisa Assays Demonstrate Specificity of Islet and Intestinal Processing of Proglucagon
por: D’Alessio, David A, et al.
Publicado: (2020)

SAT-167 Intra-Islet Ghrelin Signaling Does Not Regulate Insulin Secretion from Adult Mice
por: Gray, Sarah, et al.
Publicado: (2019)

SAT-163 Prolactin Receptor Signaling Regulates a Pregnancy-Specific Transcriptional Program in Mouse Islets
por: Pepin, Mark, et al.
Publicado: (2019)

SAT-158 Offspring Exposed to Maternal High Fat Diet Exhibits Systemic Inflammation and Pancreatic Islet Dysfunction
por: Casasnovas, Jose, et al.
Publicado: (2019)

SAT-161 Macrophage Alterations in Islets of Obese Mice Linked to Beta Cell Compensation or Beta Cell Dedifferentiation in Diabetes
por: Chan, Jeng Yie, et al.
Publicado: (2019)

Young Adult LEW.1WR1 Rats Develop Dysregulated Islet Function and Impaired Liver Insulin Responses
por: Wilkerson-Vidal, Quiana C, et al.
Publicado: (2021)

SUN-164 Use of Metformin, Premixed Insulin, and Glucagon-Like Peptide-1 Receptor Agonist as a Therapeutic Approach for Uncontrolled Type 2 Diabetes Mellitus
por: Fazeli, Sasan, et al.
Publicado: (2019)

SUN-640 Sex-Specific Difference in REG3G Expression Directs the Maintenance of Islet Function in Offspring of Obese Mice
por: Casasnovas, Jose, et al.
Publicado: (2020)

Anaphylactic Reaction to Dulaglutide: A Glucagon Like Peptide- 1 Receptor Agonist
por: Quadri, Hamza, et al.
Publicado: (2021)

Management of Late Dumping Syndrome Induced Hypoglycemia With GLP-1R Agonist
por: Shaghouli, Amna Ali, et al.
Publicado: (2021)

OR14-01 FSTL3 Neutralizing Antibodies Restore Function to Diabetic Mouse and Human Islets: A New Approach for Treating Diabetes
por: Schneyer, Alan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bu6remkph4o5a11k3jr2p4mdfk